Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 8/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 8/20 | 0.36 |
| ▸ | BRD4 | O60885 | 5/20 | 0.36 |
| ▸ | BPTF | Q12830 | 2/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | BRD1 | O95696 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.31 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.31 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.31 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
| ▸ | VNN1 | O95497 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL3119239 | 0.93 | BRD4 (0.32) | BRD9KAT2BBRD4BPTFALDH1A1 | |
| Carbamic Acid SCHEMBL3119184 | 0.93 | BRD4 (0.32) | BRD9KAT2BBRD4BPTFALDH1A1 | |
| SCHEMBL6065834 | 0.81 | LPAR1 (0.36) | BRD9KAT2BBRD4BPTFLPAR1 | |
| SCHEMBL4199889 | 0.81 | GAA (0.32) | — | |
| SCHEMBL3119092 | 0.81 | LPAR1 (0.38) | BRD9KAT2BBRD4BPTFALDH1A1 | |
| SCHEMBL4205063 | 0.80 | ALDH1A1 (0.36) | BRD9KAT2BBRD4BPTFKCNN4 | |
| SCHEMBL6065837 | 0.80 | LPAR1 (0.37) | BRD9KAT2BBRD4BPTFALDH1A1 | |
| SCHEMBL6425412 | 0.80 | ALDH1A1 (0.37) | BRD9KAT2BBRD4BPTFALDH1A1 | |
| SCHEMBL5500962 | 0.76 | ADRA2C (0.39) | BRD9KAT2BBRD4BPTFLPAR1 | |
| SCHEMBL6425423 | 0.76 | HPGD (0.40) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| US-20090012054-A1 | Cephem Compounds and Use as Antimicrobial Agents | ASTELLAS PHARMA INC. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1994035-A1 | CEPHEM COMPOUNDS AND USE AS ANTIMICROBIAL AGENTS | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007119511-A1 | CEPHEM COMPOUNDS AND USE AS ANTIMICROBIAL AGENTS | ASTELLAS PHARMA INC. (JP) | 2007-10-25 | — | — | WO | disclosed |
| CN-100343260-C | Cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2007-10-17 | — | — | CN | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| CN-1708502-A | Cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-12-14 | — | — | CN | disclosed |
| EP-1556389-A1 | CEPHEM COMPOUNDS | Astellas Pharma Inc. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039814-A1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | BRD9 3009/4885KAT2B 328/4885BRD4 3535/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | BRD9 2975/4885KAT2B 488/4885BRD4 3504/4885 |
| US-20090012054-A1 | Cephem Compounds and Use as Antimicrobial Agents | CEP170, Q6ZSR9, H1-10 | BRD9 790/4885KAT2B 712/4885BRD4 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.